Pediatric Nonalcoholic Fatty Liver Disease: Current Thinking

被引:22
|
作者
Nobili, Valerio [1 ,2 ,3 ]
Socha, Piotr [4 ]
机构
[1] Bambino Gesu Children Hosp, Hepatometabol Dis Unit, Rome, Italy
[2] Bambino Gesu Children Hosp, Liver Res Unit, Rome, Italy
[3] Univ Roma La Sapienza, Pediat Dept, Rome, Italy
[4] Childrens Mem Hlth Inst, Dept Gastroenterol Hepatol Nutr Disorders & Pe, Al Dzieci Polskich 20, PL-04730 Warsaw, Poland
来源
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION | 2018年 / 66卷 / 02期
关键词
fibrosis; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; steatosis; CONTROLLED ATTENUATION PARAMETER; ESPGHAN HEPATOLOGY COMMITTEE; LIFE-STYLE INTERVENTION; CONTROLLED-TRIAL; OBESE CHILDREN; VITAMIN-E; BARIATRIC SURGERY; CLINICAL-TRIAL; ADOLESCENTS; STEATOHEPATITIS;
D O I
10.1097/MPG.0000000000001823
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic fatty liver disease (NAFLD), an increasingly prevalent paediatric disorder, is diagnosed and managed not only by both pediatric gastroenterologists/hepatologists but also frequently by the general pediatrician. This article updates recent advances in diagnostic and therapeutic approach, which may be applied to everyday practice. Diagnosis of NAFLD takes into account the risk factor profile and is a diagnosis of exclusion. Techniques such as transient elastography and specific biomarkers aimed at improving diagnosis and monitoring of NAFLD need further validation in the pediatric population. Defining the risk to develop cirrhosis seems to be of primary importance already in childhood and a combination of genetic, clinical, and environmental factors can help in monitoring and making decisions on therapy. Weight reduction therapy should be the aim of treatment approach, but the compliance is poor and pharmacological treatment would be helpful; docosahexaenoic acid, some probiotics, and vitamin E are to be considered, but evidence is not sufficient to recommend widespread use.
引用
收藏
页码:188 / 192
页数:5
相关论文
共 50 条
  • [41] Current and Emerging Therapies in Nonalcoholic Fatty Liver Disease
    Kashi, Maryam R.
    Torres, Dawn M.
    Harrison, Stephen A.
    SEMINARS IN LIVER DISEASE, 2008, 28 (04) : 396 - 406
  • [42] Nonalcoholic Fatty Liver Disease: Current Global Burden
    El-Kassas, Mohamed
    Cabezas, Joaquin
    Iruzubieta Coz, Paula
    Zheng, Ming-Hua
    Pablo Arab, Juan
    Awad, Abeer
    SEMINARS IN LIVER DISEASE, 2022, 42 (03) : 401 - 412
  • [43] Nonalcoholic fatty liver disease: Synopsis of current developments
    Onyekwere, C. A.
    Ogbera, A. O.
    Samaila, A. A.
    Balogun, B. O.
    Abdulkareem, F. B.
    NIGERIAN JOURNAL OF CLINICAL PRACTICE, 2015, 18 (06) : 703 - 712
  • [44] Current status of imaging in nonalcoholic fatty liver disease
    Qian Li
    Manish Dhyani
    Joseph R Grajo
    Claude Sirlin
    Anthony E Samir
    World Journal of Hepatology, 2018, 10 (08) : 530 - 542
  • [45] Obesity and nonalcoholic fatty liver disease: current perspectives
    Sarwar, Raiya
    Pierce, Nicholas
    Koppe, Sean
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2018, 11 : 533 - 542
  • [46] Current best treatment for nonalcoholic fatty liver disease
    Angulo, P
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (05) : 611 - 623
  • [47] Current management of patients with nonalcoholic fatty liver disease
    Elsheikh, Elzafir
    Henry, Linda L.
    Younossi, Zobair M.
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2013, 8 (06) : 549 - 558
  • [48] Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease
    Ganesh, Swaytha
    Rustgi, Vinod K.
    CLINICS IN LIVER DISEASE, 2016, 20 (02) : 351 - +
  • [49] Current concepts in the pathogenesis of nonalcoholic fatty liver disease
    Mendez-Sanchez, Nahum
    Arrese, Marco
    Zamora-Valdes, Daniel
    Uribe, Misael
    LIVER INTERNATIONAL, 2007, 27 (04) : 423 - 433
  • [50] Current treatment options for nonalcoholic fatty liver disease
    Shetty, Akshay
    Syn, Wing-Kin
    CURRENT OPINION IN GASTROENTEROLOGY, 2019, 35 (03) : 168 - 176